Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer patients.

The most common reason for cisplatin-ineligibility is renal function impairment. Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min ...

Patients were given either standard chemotherapy (cisplatin and gemcitabine ... study describe this as a significant breakthrough in bladder cancer treatment, and hope it will be approved by ...

Patients with advanced bladder cancer treated with an immunosuppressant drug were a third less likely to see the disease return and more likely to survive for longer than patients who were given ...

could help reduce the risk of bladder cancer progressing or returning to patients, according to a new study. Patients were given either standard chemotherapy (cisplatin and gemcitabine ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

which involved 1,063 patients with operable bladder cancer, compared the outcomes of patients who received standard chemotherapy (cisplatin and gemcitabine) and surgery, to those who received ...

Bladder cancer is one of the most common type ... Patients were given either standard chemotherapy (cisplatin and gemcitabine) and surgery (530 people), or chemotherapy plus durvalumab before ...